T cells go universal

National University of Singapore and St. Jude Children's Research Hospital team has engineered a T cell therapeutic that can engage in antibody-dependent cell cytotoxicity and enhance the effects of therapeutic antibodies regardless of the target tumor antigen.¹ The researchers showed proof of concept for boosting the efficacy of multiple marketed cancer antibodies.

They now plan to test T cell and antibody combinations in clinical trials in which antibody monotherapy did not generate remissions...